Opioid prescription and diabetes among Medicare beneficiaries

Diabetes Res Clin Pract. 2023 Feb:196:110240. doi: 10.1016/j.diabres.2023.110240. Epub 2023 Jan 4.

Abstract

Aims: To determine the prevalence of opioid prescriptions among U.S. Medicare beneficiaries by diabetes status, and predictors of opioid prescription among those with diabetes.

Methods: This retrospective study used claims data from the Centers for Medicare and Medicaid Services among beneficiaries age ≥ 65 years who were continuously enrolled in Part A, Part B, and Part D Medicare between 2017 and 2019 (N = 709,374). Logistic regression was used to determine the odds of opioid prescription among those with vs without diabetes; and, among those with diabetes, significant predictors of opioid prescription.

Results: Overall, the prevalence of any opioid prescription was 30.8 % among persons with diabetes and 24.2 % in those without diabetes (p < 0.001); chronic use was 8.0 % and 7.4 %, respectively (p < 0.001). Those with diabetes had a 45 % higher odds of having an opioid prescription compared to those without diabetes after adjusting for sociodemographic characteristics (OR = 1.45, 1.44-1.47). After adjustment for comorbidities/complications, the association reversed (OR = 0.83, 0.82-0.84). Persons with diabetes who had hypertension, obesity, CVD, neuropathy, amputation, liver disease, COPD, cancer, osteoporosis, depression, or alcohol/drug abuse had a 20 %-140 % higher odds of opioid prescription compared to those without these conditions.

Conclusions: Comorbidities and complications accounted for the higher odds of opioid prescriptions among those with diabetes.

Keywords: Comorbidities; Medicare; Opioids.

MeSH terms

  • Aged
  • Analgesics, Opioid* / therapeutic use
  • Diabetes Mellitus* / drug therapy
  • Drug Prescriptions
  • Humans
  • Medicare
  • Retrospective Studies
  • United States

Substances

  • Analgesics, Opioid